Global  

COVID-19 vaccine candidate approved for military use in China

WorldNews Monday, 29 June 2020 ()
COVID-19 vaccine candidate approved for military use in ChinaChina's military has received the greenlight to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy, the company said on Monday. The Ad5-nCoV is one of China's eight vaccine candidates approved for human trials...
0
shares
ShareTweetSavePostSend
 
Video credit: Wochit Business - Published
News video: China Approves COVID-19 Vaccine For Military Use

China Approves COVID-19 Vaccine For Military Use 00:30

The Chinese government has announced the approval of an experimental Covid-19 vaccine. According to CNN, the new vaccine is only approved for use in the country's military personnel. The vaccine, known as Ad5-nCoV was developed by the Beijing Institute of Biotechnology and CanSino Biologics. CanSino...

You Might Like


💡 One News Page Knowledge: Other News Mentions

CanSino Biologics CanSino Biologics Chinese vaccine company

China Approves COVID-19 Vaccine For Human Trials In Military Personnel [Video]

China Approves COVID-19 Vaccine For Human Trials In Military Personnel

Chinese officials have announced the approval of a COVID-19 vaccine for immediate use by military personnel. According to UPI. the vaccine, Ad5-nCoV is currently being studied in clinical trials. There is no word yet on how many of the 2.2 million Chinese military members will receive the vaccine. Ad5-nCoV was developed by the Beijing Institute of Biotechnology, and biotechnology firm CanSino Biologics. Globally there have been over 10 million confirmed cases of the novel coronavirus.

Credit: Wochit News    Duration: 00:30Published
Coronavirus Vaccine From China Is Safe In Early Trial [Video]

Coronavirus Vaccine From China Is Safe In Early Trial

A coronavirus vaccine developed by CanSino Biologics Inc appears to be safe. It induced a rapid immune response in its first human trial, Reuters reports. This vaccine did not cause any serious adverse effects, though side effects such as fever were noted. Blood samples from the 108 vaccinated adults showed "neutralizing antibodies" and T-cell responses. However, the ability to trigger these immune responses does not necessarily indicate that the vaccine works.

Credit: Wochit News    Duration: 00:39Published

Related videos from verified sources

Scientists Eye TB Vaccine As Weapon To Battle COVID-19 [Video]

Scientists Eye TB Vaccine As Weapon To Battle COVID-19

New research supports the use of the tuberculosis vaccine Bacillus Calmette-Guerin (BCG) as a tool in the fight against the novel coronavirus COVID-19. According to CNN researchers found that countries..

Credit: Wochit Entertainment     Duration: 00:34Published
Watch: Tibetan Youth Congress protests against China in Dharamshala [Video]

Watch: Tibetan Youth Congress protests against China in Dharamshala

The Tibetan Youth Congress held protests against China in Dharamshala. They raised slogans against the Chinese government and held 'boycott Chinese goods' posters. Some of them were also seen breaking..

Credit: HT Digital Content     Duration: 01:30Published
Covid update: Probe team to visit China; US varsities vs Trump govt; $4 bn aid [Video]

Covid update: Probe team to visit China; US varsities vs Trump govt; $4 bn aid

From a World Health Organisation team set to visit China to search for the Covid-19 virus' origin, to Prime Minister Narendra Modi wishing Brazil President Jair Bolsonaro a speedy recovery - here are..

Credit: HT Digital Content     Duration: 03:39Published

Related news from verified sources

Covid 19 coronavirus: Vaccine candidate approved for military use in China

Covid 19 coronavirus: Vaccine candidate approved for military use in China
China's military has been given the green light to use a Covid-19 vaccine candidate, after clinical trials yielded positive results.The vaccine, developed by the...
New Zealand Herald Also reported by •Jerusalem PostCBC.ca

Tweets about this